Healthcare Review: PharmAthene, Inovio Pharmaceuticals, MannKind, Merrimack Pharmaceuticals, Salix Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Monday, 11 August 2014 13:58

U.S. shares rose modestly in Monday trading, continuing a recovery from a brief correction that ended Friday as investors focused on hopes for easing tensions between Ukraine and Russia.

Consumer staples shares led the gains, with a 1 percent increase for that sector. The best performing name was food service company Sysco Corp, which rose 3.7 percent after its results.

Shares of thinly-traded PharmAthene ($PIP) jump on a 40x surge in volume after the Delaware Court of Chancery ruled in favor of the company in its lawsuit versus Siga Technologies (SIGA -34.7%). The Court awarded PharmAthene lump sum damages for the value of its lost Tecovirimat profits plus a portion of its litigation expenses.

Inovio Pharmaceuticals ($INO) Q2 results: Revenues: $3.8M (+383.9%); Operating Expenses: $14.0M (+116.1%); Operating Loss: ($10.2M) (-79.0%); Net Loss: ($10.7M) (+1.4%); Loss Per Share: ($0.19) (+8.3%); Quick Assets: $108.8M (+106.8%).

MannKind ($MNKD) Q2 results: Revenues: $0; Operating Expenses: $69.8M (+67.8%); Operating Loss: ($69.8M) (-67.8%); Net Loss: ($73.4M) (-59.2%); Loss Per Share: ($0.19) (-18.8%); Quick Assets: $41.2M (-41.8%).

Merrimack Pharmaceuticals (NASDAQ:MACK) Q2 results: Revenues: $27.8M (+50.3%); Operating Expenses: $41.7M (-12.4%); Operating Loss: ($13.9M) (+52.2%); Net Loss: ($18.1M) (+39.7%); Loss Per Share: ($0.17) (+45.2%); Quick Assets: $92.7M (-40.3%); Cash Burn: ($32.8M) (-35.5%).The company expects its current financial assets and revenue from its Sanofi collaboration will be sufficient to fund operations into 2015.

The FDA assigns a PDUFA date of September 29, 2014 for Salix Pharmaceuticals' (NASDAQ:SLXP) sNDA for Relistor (methylnaltrexone bromide) for treatment of opioid-induced constipation.Salix successfully appealed a CRL that the agency issued on July 27, 2012.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter